Last C$0.60 CAD
Change Today -0.03 / -4.76%
Volume 253.1K
MBX On Other Exchanges
Symbol
Exchange
Toronto
OTC US
Frankfurt
As of 4:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

microbix biosystems inc (MBX) Snapshot

Open
C$0.63
Previous Close
C$0.63
Day High
C$0.64
Day Low
C$0.58
52 Week High
11/20/14 - C$0.90
52 Week Low
03/12/14 - C$0.35
Market Cap
47.6M
Average Volume 10 Days
150.0K
EPS TTM
C$0.0019
Shares Outstanding
79.3M
EX-Date
--
P/E TM
315.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for MICROBIX BIOSYSTEMS INC (MBX)

Related News

No related news articles were found.

microbix biosystems inc (MBX) Related Businessweek News

No Related Businessweek News Found

microbix biosystems inc (MBX) Details

Microbix Biosystems Inc. develops, manufactures, and sells biological products and technologies in North America, Europe, and internationally. The company manufactures and sells cell culture-based biological products, as well as infectious disease antigens. It offers infectious disease antigens, such as viral, bacterial, and parasitic products used in various applications, including immunodiagnostic assays; basic and applied research in virology, microbiology, cell biology, molecular biology, immunology, and pathology; as controls and calibrators for a range of medical devices; and for vaccine and antiviral research and development. In addition, the company provides adenovirus vectors, cells, and services to biopharmaceutical and biotechnology researchers and companies, as well as provides facility, technical, and production personnel for contract research and development. Its pipeline of technologies and products includes LumiSort semen sexing technology for the livestock industries; Kinlytic, a thrombolytic drug with various approved and potential applications, including the treatment of life-threatening blood clots, and VIRUSMAX, a proprietary technology for increasing virus yields in the manufacture of influenza vaccine. The company offers products for human health applications, namely in the vaccine, therapeutic, and diagnostic markets, as well as animal reproductive markets. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

Founded in 1988

microbix biosystems inc (MBX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$212.4K
Founder, Executive Chairman and Member of Hum...
Total Annual Compensation: C$197.3K
Chief Financial Officer
Total Annual Compensation: C$14.1K
Senior Vice President of Sales & Business Dev...
Total Annual Compensation: C$177.5K
Vice President of Biotherapeutics
Total Annual Compensation: C$153.0K
Compensation as of Fiscal Year 2013.

microbix biosystems inc (MBX) Key Developments

Microbix Biosystems Inc. Reports Financial Results for the Fourth Quarter and Full Year Ended September 30, 2014

Microbix Biosystems Inc. reported financial results for the fourth quarter and full year ended September 30, 2014. In the fourth quarter, the company reported revenue of $2,355,879 compared to $2,468,899 for the same quarter in 2013. Operating loss before income taxes was $302,963 compared with operating profit before tax was $571,932 a year ago. Net loss was $351,621 compared with net profit was $405,132 a year ago. Net loss per share were $0.004 compared with Net earnings per share were $0.006 a year ago. Cash flow was $95,410 compared with $105,931 a year ago. Full year revenues were $8,396,796 compared with $7,574,593 a year ago. Operating profit before income taxes was $475,624 compared with $168,178 a year ago. Net profit was $168,979 compared with $1,378 a year ago. Net earnings per share were $0.002 compared with $0.000 a year ago. Cash flow was $287,308 compared with $31,619 a year ago.

Microbix Biosystems Inc. Reports Financial Results for the Third Quarter and Nine Months Ended June 30, 2014

Microbix Biosystems Inc. reported financial results for the third quarter and nine months ended June 30, 2014. For the quarter, the company reported total revenue of $2,039,935, compared to $1,906,652 for the same period in 2013, or an increase of 7%. Operating income before income taxes for the second quarter was $294,561 compared to an operating loss of $22,687 for the same quarter last year. Net cash flow decreased in the third quarter by $697,719, compared to a decrease of $71,931 for the same period in 2013. The decline was primarily due to the investment in property, plant and equipment, primarily to build the LumiSort(TM) demonstration instrument; as well as intangible assets, in defense of the VIRUSMAX(R) patents, totaling $1,467,802; partially offset by the conversion of warrants during the quarter of $545,511 and the improvement in operating cash flow of $212,923. Net income of $210,567 or $0.003 per share against net loss was $22,687 a year ago. For the nine months, the company reported total revenue of $6,040,917, compared to $5,105,693 for the same period in 2013, or an increase of 18%. Operating income before income taxes for nine months was $778,587, compared to an operating loss of $403,755 for the same period last year, or an improvement in the bottom line of $1,182,342. Net cash flow increased by $191,899 compared to a decrease of $175,667 for the same period in 2013, contributing to an improvement in the company's ending cash position of $399,186. Net income of $520,600 or $0.008 per share against net loss was $403,755 or $0.006 per share a year ago.

Microbix Biosystems Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2014

Microbix Biosystems Inc. reported earnings results for the second quarter and six months ended March 31, 2014. For the six months, the company reported revenue of $4,000,982, compared to $3,199,041 for the same period in 2013, or an increase of 25%. Operating income was $484,026, compared to an operating loss of $321,034 for the same period last year, or an improvement in the bottom line of $805,060. Net cash flow was $889,619, compared to net cash out flow of $103,736 for the same period in 2013, contributing to an improvement in the company's ending cash position of $1,024,974. The company reported net income of $310,033 or $0.0046 per share compared to net loss of $381,068 or $0.0054 per share for the last year. For the quarter, the company reported revenue of $2,073,097, slightly below the total revenue of $2,103,426 for the same period in 2013. Operating income for the second quarter was $269,620 compared to $308,471 for the same quarter last year. Net cash flow of $941,391, compared to net cash out flow of $49,992 for the same period in 2013. The improvement was primarily due to the receipt of proceeds from the LumiSort(TM) convertible debenture of $1,500,000, the conversion of warrants and stock options of $543,335, and the release of restricted cash of $250,000 by the Company's bank; this was offset by a reduction in bank loans of $176,003 plus additional investment in new property, equipment and intangible assets of $863,245. The company reported net income of $193,872 or $0.0029 per share compared to $248,437 or $0.0037 per share for the last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MBX:CN C$0.60 CAD -0.03

MBX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MBX.
View Industry Companies
 

Industry Analysis

MBX

Industry Average

Valuation MBX Industry Range
Price/Earnings 100.0x
Price/Sales 4.8x
Price/Book 4.3x
Price/Cash Flow 262.3x
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MICROBIX BIOSYSTEMS INC, please visit www.microbix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.